Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...
After the U.S. Congress pulled funding for a few pediatric cancer programs from the bill passed last week to fund the government through March 14, the Senate voted unanimously to restore a $12.6 ...
The FDA granted accelerated approval to encorafenib (Braftovi; Array BioPharma/Pfizer), a BRAF inhibitor, in combination with the anti-EGFR mAb cetuximab (Erbitux; Eli Lilly) and the chemotherapy ...
Copyright held by the owner/author(s).
The cereblon E3 ligase modulator cemsidomide showed activity against multiple myeloma and two types of non–Hodgkin lymphoma in a phase I study.
Machine learning could better stratify patients with metastatic ER-positive, HER2-negative breast cancer who are more or less likely to benefit from CDK4/6 inhibition up front. At Memorial Sloan ...
Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...
1Medical Clinic III for Oncology, Hematology, Immune-Oncology and Rheumatology, University Hospital Bonn, Bonn, Germany.
Major Finding: In breast cancer, chemotherapy elicits stronger antitumor responses when administered during estrus. Concept: The estrous cycle alters macrophage infiltration, epithelial-mesenchymal ...
Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...
Major Finding: Pharmacologic inhibition of EZH2 sensitizes preclinical models of B cell lymphoma to T-cell immunotherapy. Concept: EZH2 inhibition enhances T-cell recruitment, T-cell–B-cell ...
Division of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback